Dr. Zamarin on Lenvatinib Plus Pembrolizumab in Endometrial Cancer

Dmitriy Zamarin, MD, PhD
Published: Wednesday, Sep 20, 2017



Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in endometrial cancer.

This combination has been evaluated in patients with endometrial cancer and renal cell carcinoma, results of which were presented at the 2017 ASCO Annual Meeting and the 2017 EMSO Congress, respectively. Results in both trials demonstrated promising response rates and progression-free survival, Zamarin says.

The rationale for combining these drugs is not completely clear, says Zamarin, but these trials prove how little is known about the potential of drugs not initially developed to target the immune system.
 


Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in endometrial cancer.

This combination has been evaluated in patients with endometrial cancer and renal cell carcinoma, results of which were presented at the 2017 ASCO Annual Meeting and the 2017 EMSO Congress, respectively. Results in both trials demonstrated promising response rates and progression-free survival, Zamarin says.

The rationale for combining these drugs is not completely clear, says Zamarin, but these trials prove how little is known about the potential of drugs not initially developed to target the immune system.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x